(Alliance News) - Oncimmune Holdings PLC on Monday said it had signed an autoantibody profiling agreement with a large pharmaceutical company, but did not provide the partner's name or disclose any financial details of the deal.
The agreement will allow Oncimmune to assess autoantibody profiles of patient samples in various autoimmune diseases through NavigAID, its autoimmune disease characterisation panel.
The Nottingham-based immunodiagnostics developer added this is the second agreement it has struck with the partner.
Shares were down 8.4% at 174.00 pence in London on Monday afternoon.
The initial phase of the project, including the reporting of profiled data, should complete by the end of 2021. It will primarily explore the antibody profiles of people with systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis and sicca syndrome.
"We are delighted that this global pharmaceutical company has again chosen to partner with Oncimmune, for our world class autoantibody biomarker profiling technology and autoimmune expertise," said Oncimmune Chief Executive Adam Hill.
"We are confident that this latest programme will form part of a larger and long-term collaboration and we look forward to supporting their programmes in immunology further through clinical development."
Oncimmune in late July signed a similar profiling contract with Boston, Massachusetts-based Dana-Farber Cancer Institute, a clinical affiliate and research institute of Harvard Medical School.
Hill added that Oncimmune is focusing investment on "physical and human infrastructure" and noted a pipeline of more conversions in the coming months.
By Josie O'Brien; josieobrien@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Oncimmune (ONC)